Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.
Remepy’s hybrid Parkinson’s therapy poised for phase 3
Remepy’s Hybridopa therapy for Parkinson’s, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

